Pharma & Life Science

Today’s pharmaceutical companies face immense pressure to effectively deliver products that are safe, valuable to patients, and cost-effective. Life science companies are now being asked not just to develop new therapies, but to identify the patients who will most benefit from those treatments. Targeting the right patients for clinical trials is essential for passing the constantly rising bar for FDA approval. After approval, patients and payers are demanding real-world evidence of drug effectiveness and asking pharmaceutical companies to back that up with risk sharing agreements and value-based contracts.

Advances in artificial intelligence and new and emerging data sources now allow pharmaceutical companies to gain significant efficiencies in the targeting of new therapies and to demonstrate the value of late-stage clinical and newly approved products.

What We Do

ClosedLoop’s data science platform combines leading-edge AI tools and automation capabilities with healthcare specific content and expertise - enabling healthcare data scientists to build accurate and explainable predictive models with speed and ease.

  • icon


    ClosedLoop’s data science platform uses a variety of data sources to create accurate predictions and surface new insights.

  • icon


    Don’t reinvent the wheel. ClosedLoop’s catalog of risk models cover the most common and valuable use cases and are fully editable and extensible to meet your needs. No data-science degree required.

  • icon


    Easily create risk-scores and predictions for a variety of outcomes in just a few clicks, or use the API and be up and running in under an hour.

  • icon


    Explore the predictive value of your data without a large upfront investment of time or money. Ask about the 24-hour zero-risk pilot today.

The ClosedLoop Platform for Pharma & Life Science

ClosedLoop’s data science platform is a healthcare-specific AI-based predictive analytics platform that uncovers insights in vast amounts of disparate healthcare data, including clinical trials, real-world clinical and claims data, genomic, social, and environmental data. ClosedLoop can identify biomarkers that are predictive of treatment response, and select patient groups most likely to benefit from treatment. ClosedLoop continues to get smarter as it absorbs more data – identifying new relationships and novel insights. ClosedLoop’s platform can be used to answer questions like:

  • Biomarkers:  Which patients will have an increased success rate based on biological factors?
  • Drug-Combinations:  Which drug combinations are most likely to be successful?
  • Segmentation:  Which groups of patients respond differently to treatment?
  • Strategy:  Which subpopulations should be included/excluded based on predicted success rates?
  • Responsive:  Which patients are responding to treatment?
  • Events:  Which patients are most likely to experience adverse reactions?
  • Effectiveness:  How will clinical trial results translate into real-world effectiveness?
  • Value:  What improvement in outcomes will a new treatment generate over existing therapies?
  • Switching:  Which factors are most relevant in understanding which patients switch drugs?
  • Marketing:  Which physicians can we market to?
see the platform in action

Proof of Concept in 5 Easy Steps

How Can ClosedLoop Help Improve Patient Outcomes & Lower the Total Cost of Care For Your Organization?

Get in touch today to speak with a member of the ClosedLoop team

talk to an expert